

October 2024

BCBSAL Prior Authorization Utilization Management

Prior Authorization

Certain drugs require prior authorization to help promote safe, quality and affordable pharmacy care. Your doctor will need to submit a prior authorization request to Prime Therapeutics, which must be approved before you can continue to receive coverage for these drugs.

The Prior Authorization form that your physician will need to complete to request an approval can be found on the MyPrime website.

Quantity Limit Consideration

Within the Prior Authorization program, Quantity Limit may apply. If there is medical reason why you need an amount that is greater than what is allowed, your physician can fill out a Quantity Limit prior authorization form for you and send it to Prime Therapeutics. This form can be found on the MyPrime.com website.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Acute Migraine Agents		dihydroergotamine mesylate
		ELYXYB
		MIGRANAL
		REYVOW
		TRUDHESA
Afrezza		AFREZZA
Agamree Emflaza		AGAMREE
		deflazacort
		EMFLAZA
Amantadine ER		GOCOVRI
		OSMOLEX ER
Amifampridine		FIRDAPSE
Ampyra		AMPYRA
		dalfampridine er
Androgen/Anabolic Steroids		ANDRODERM
		ANDROGEL
		ANDROGEL PUMP
		danazol

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		FORTESTA
		JATENZO
		KYZATREX
		METHITEST
		methylestosterone
		NATESTO
		TESTIM
		TESTOSTERONE
		TESTOSTERONE PUMP
		testosterone topical solution
		TLANDO
		VOGELXO
		VOGELXO PUMP
Arikayce		ARIKAYCE
ATTR Amyloidosis		TEGSEDI
		VYNDAMAX
		VYNDAQEL
		WAINUA
Baclofen		BACLOFEN
		FLEQSUVY
		LYVISPAH
		OZOBAX
		OZOBAX DS
Bempedoic Acid		NEXLETOL
		NEXLIZET
Biologic Immunomodulators	Preferred Products: Refer to Policy	ABRILADA
	Preferred Products: Refer to Policy	ABRILADA 1-PEN KIT
	Preferred Products: Refer to Policy	ABRILADA 2-PEN KIT
	Preferred Products: Refer to Policy	ACTEMRA
	Preferred Products: Refer to Policy	ACTEMRA ACTPEN
	Preferred Products: Refer to Policy	ADALIMUMAB-AACF (2 PEN)
	Preferred Products: Refer to Policy	ADALIMUMAB-AATY 1-PEN KIT
	Preferred Products: Refer to Policy	ADALIMUMAB-AATY 2-PEN KIT
	Preferred Products: Refer to Policy	ADALIMUMAB-AATY 2-SYRINGE KIT
	Preferred Products: Refer to Policy	ADALIMUMAB-ADAZ
	Preferred Products: Refer to Policy	ADALIMUMAB-ADBIM
	Preferred Products: Refer to Policy	ADALIMUMAB-ADBIM CROHNS/UC/HS STARTER

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Refer to Policy	ADALIMUMAB-ADBIM PSORIASIS/UVEITIS STARTER
	Preferred Products: Refer to Policy	ADALIMUMAB-ADBIM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS
	Preferred Products: Refer to Policy	ADALIMUMAB-ADBIM STARTER PACKAGE FOR PSORIASIS/UVEITIS
	Preferred Products: Refer to Policy	ADALIMUMAB-FKJP
	Preferred Products: Refer to Policy	ADALIMUMAB-RYVK (2 PEN)
	Preferred Products: Refer to Policy	AMJEVITA
	Preferred Products: Refer to Policy	BIMZELX
	Preferred Products: Refer to Policy	CIMZIA
	Preferred Products: Refer to Policy	CIMZIA STARTER KIT
	Preferred Products: Refer to Policy	COSENTYX
	Preferred Products: Refer to Policy	COSENTYX SENSOREADY PEN
	Preferred Products: Refer to Policy	COSENTYX UNOREADY
	Preferred Products: Refer to Policy	CYLTEZO
	Preferred Products: Refer to Policy	CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS
	Preferred Products: Refer to Policy	CYLTEZO STARTER PACKAGE FOR PSORIASIS
	Preferred Products: Refer to Policy	CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS
	Preferred Products: Refer to Policy	ENBREL
	Preferred Products: Refer to Policy	ENBREL MINI
	Preferred Products: Refer to Policy	ENBREL SURECLICK
	Preferred Products: Refer to Policy	ENTYVIO
	Preferred Products: Refer to Policy	HADLIMA
	Preferred Products: Refer to Policy	HADLIMA PUSHTOUCH
	Preferred Products: Refer to Policy	HULIO
	Preferred Products: Refer to Policy	HUMIRA
	Preferred Products: Refer to Policy	HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK
	Preferred Products: Refer to Policy	HUMIRA PEN
	Preferred Products: Refer to Policy	HUMIRA PEN-CD/UC/HS STARTER
	Preferred Products: Refer to Policy	HUMIRA PEN-PEDIATRIC UC STARTER PACK
	Preferred Products: Refer to Policy	HUMIRA PEN-PS/UV STARTER
	Preferred Products: Refer to Policy	HYRIMOZ
	Preferred Products: Refer to Policy	HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK
	Preferred Products: Refer to Policy	HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Refer to Policy	HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK
	Preferred Products: Refer to Policy	HYRIMOZ PLAQUE PSORIASIS STARTER PACK
	Preferred Products: Refer to Policy	HYRIMOZ SENSOREADY PENS
	Preferred Products: Refer to Policy	IDACIO (2 PEN)
	Preferred Products: Refer to Policy	IDACIO (2 SYRINGE)
	Preferred Products: Refer to Policy	IDACIO STARTER PACKAGE FOR CROHN'S DISEASE
	Preferred Products: Refer to Policy	IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS
	Preferred Products: Refer to Policy	KEVZARA
	Preferred Products: Refer to Policy	KINERET
	Preferred Products: Refer to Policy	LITFULO
	Preferred Products: Refer to Policy	OLUMIANT
	Preferred Products: Refer to Policy	OMVOH
	Preferred Products: Refer to Policy	ORENCIA
	Preferred Products: Refer to Policy	ORENCIA CLICKJECT
	Preferred Products: Refer to Policy	RINVOQ
	Preferred Products: Refer to Policy	RINVOQ LQ
	Preferred Products: Refer to Policy	SILIQ
	Preferred Products: Refer to Policy	SIMLANDI 1-PEN KIT
	Preferred Products: Refer to Policy	SIMLANDI 2-PEN KIT
	Preferred Products: Refer to Policy	SIMPONI
	Preferred Products: Refer to Policy	SKYRIZI
	Preferred Products: Refer to Policy	SKYRIZI PEN
	Preferred Products: Refer to Policy	SOTYKTU
	Preferred Products: Refer to Policy	STELARA
	Preferred Products: Refer to Policy	TALTZ
	Preferred Products: Refer to Policy	TREMFYA
	Preferred Products: Refer to Policy	TYENNE
	Preferred Products: Refer to Policy	VELSIPITY
	Preferred Products: Refer to Policy	XELJANZ
	Preferred Products: Refer to Policy	XELJANZ XR
	Preferred Products: Refer to Policy	YUFLYMA 1-PEN KIT
	Preferred Products: Refer to Policy	YUFLYMA 2-PEN KIT
	Preferred Products: Refer to Policy	YUFLYMA 2-SYRINGE KIT
	Preferred Products: Refer to Policy	YUFLYMA CD/UC/HS STARTER
	Preferred Products: Refer to Policy	YUSIMRY
	Preferred Products: Refer to Policy	ZYMFENTRA 1-PEN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Refer to Policy	ZYMFENTRA 2-PEN
	Preferred Products: Refer to Policy	ZYMFENTRA 2-SYRINGE
Bonjesta/Diclegis		BONJESTA
		DICLEGIS
		doxylamine succinate/pyridoxine hydrochloride
Buprenorphine Opioid Dependence		buprenorphine hcl
		buprenorphine hydrochloride
Camzyos		CAMZYOS
Cannabidiol		EPIDIOLEX
Carbaglu		CARBAGLU
		carglumic acid
CFTR		KALYDECO
		ORKAMBI
		SYMDEKO
		TRIKAFTA
CGRP	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	AIMOVIG
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	AJOVY
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	EMGALITY
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	NURTEC
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	QULIPTA
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	UBRELVY
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	ZAVZPRET
Cholestasis Pruritus		BYLVAY
		BYLVAY (PELLETS)
		LIVMARLI
Cibinqo (abrocitinib)		CIBINQO
Combination NSAID		DUEXIS
		ibuprofen/famotidine
		naproxen/esomeprazole magnesium
		VIMOVO
Constipation Agents	Preferred Products: Symproic, Trulance, Movantik	AMITIZA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Symproic, Trulance, Movantik	IBSRELA
	Preferred Products: Symproic, Trulance, Movantik	LINZESS
	Preferred Products: Symproic, Trulance, Movantik	lubiprostone
	Preferred Products: Symproic, Trulance, Movantik	MOTEGRITY
	Preferred Products: Symproic, Trulance, Movantik	MOVANTIK
	Preferred Products: Symproic, Trulance, Movantik	RELISTOR
	Preferred Products: Symproic, Trulance, Movantik	SYMPROIC
	Preferred Products: Symproic, Trulance, Movantik	TRULANCE
Corticotropin		ACTHAR
		ACTHAR GEL
		CORTROPHIN
Daybue		DAYBUE
Dojolvi		DOJOLVI
Dry Eye Disease		CEQUA
		cyclosporine
		EYSUVIS
		MIEBO
		RESTASIS
		RESTASIS MULTIDOSE
		TYRVAYA
		VEVYE
		XIIDRA
Elagolix/Relugolix		MYFEMBREE
		ORIAHNN
		ORILISSA
Elmiron		ELMIRON
Empaveli		EMPAVELI
Endari		ENDARI
		l-glutamine
Enspryng		ENSPRYNG
Eohilia		EOHILIA
Fabhalta		FABHALTA
Filspari		FILSPARI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Filsuvez		FILSUEVZ
Fintepla		FINTEPLA
Furoscix		FUROSCIX
Galafold		GALAFOLD
Gattex		GATTEX
GLP-1 Agonists	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	ADLYXIN
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	ADLYXIN STARTER PACK
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	BYDUREON BCISE
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	BYETTA
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	LIRAGLUTIDE
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	MOUNJARO
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	OZEMPIC
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	RYBELSUS
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	TRULICITY
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	VICTOZA
Growth Hormone	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	GENOTROPIN
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	GENOTROPIN MINIQUICK
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	HUMATROPE
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NGENLA
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NORDITROPIN FLEXPLO
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NUTROPIN AQ NUSPIN 10
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NUTROPIN AQ NUSPIN 20
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NUTROPIN AQ NUSPIN 5
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	OMNITROPE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SAIZEN
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SAIZENPREP RECONSTITUTIONKIT
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SEROSTIM
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SKYTROFA
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SOGROYA
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	ZOMACTON
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	ZORBTIVE
HCN Channel Blocker		CORLANOR
		ivabradine hydrochloride
Hemlibra		HEMLIBRA
Hemophilia Agents		ADVATE
		ADYNOVATE
		AFSTYLA
		ALPHANATE
		ALPHANINE SD
		ALPROLIX
		ALTUVIIIIO
		BENEFIX
		COAGADEX
		CORIFACT
		ELOCTATE
		ESPEROCT
		FEIBA
		HEMLIBRA
		HEMOFIL M
		HUMATE-P
		IDELVION
		IXINITY
		JIVI
		KOATE
		KOATE-DVI
		KOGENATE FS
		KOVALTRY
		NOVOEIGHT

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		NOVOSEVEN RT
		NUWIQ
		OBIZUR
		PROFILNINE
		REBINYN
		RECOMBIMATE
		RIXUBIS
		SEVENFACT
		TRETTEN
		VONVENDI
		WILATE
		XYNTHA
		XYNTHA SOLOFUSE
Hepatitis C Direct Acting Antivirals	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	EPCLUSA
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	HARVONI
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	LEDIPASVIR/SOFOSBUVIR
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	MAVYRET
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	SOFOSBUVIR/VELPATASVIR
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	SOVALDI
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	VIEKIRA PAK
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized	VOSEVI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	ZEPATIER
Hereditary Angioedema		BERINERT
		FIRAZYR
		HAEGARDA
		icatibant acetate
		KALBITOR
		ORLADEYO
		RUCONEST
		sajazir
		TAKHZYRO
Hetlioz		HETLIOZ
		HETLIOZ LQ
		tasimelteon
HoFH Agents		JUXTAPID
HSDD		ADDYI
		VYLEESI
Hyftor		HYFTOR
Hyperhidrosis		QBREXZA
		SOFDRA
Imcivree		IMCIVREE
Inhaled Antibiotics		BETHKIS
		CAYSTON
		KITABIS PAK
		TOBI
		TOBI PODHALER
		TOBRAMYCIN
Interleukin (IL)-1 Inhibitors		ARCALYST
Interleukin (IL)-4 Inhibitors		DUPIXENT
Interleukin (IL)-5 Inhibitors		FASENRA PEN
		NUCALA
Interleukin-13 (IL-13) Antagonist		ADBRY
Interstitial Lung Disease		ESBRIET

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		OFEV
		PIRFENIDONE
Iron Chelation	Preferred Products: Exjade, Jadenu	deferasirox
	Preferred Products: Exjade, Jadenu	deferiprone
	Preferred Products: Exjade, Jadenu	EXJADE
	Preferred Products: Exjade, Jadenu	FERRIPROX
	Preferred Products: Exjade, Jadenu	FERRIPROX TWICE-A-DAY
	Preferred Products: Exjade, Jadenu	JADENU
	Preferred Products: Exjade, Jadenu	JADENU SPRINKLE
Isturisa		ISTURISA
Ivermectin		ivermectin
		STROMEKTOL
Joenja		JOENJA
Jynarque		JYNARQUE
Kerendia		KERENDIA
Korlym		KORLYM
		mifepristone
Long Acting Insulin	Preferred Products: Tresiba	INSULIN DEGLUDEC
	Preferred Products: Tresiba	INSULIN DEGLUDEC FLEXTOUCH
	Preferred Products: Semglee, Insulin glargine-yfgn	INSULIN GLARGINE
	Preferred Products: Semglee, Insulin glargine-yfgn	INSULIN GLARGINE SOLOSTAR
	Preferred Products: Semglee, Insulin glargine-yfgn	LANTUS
	Preferred Products: Semglee, Insulin glargine-yfgn	LANTUS SOLOSTAR
	Preferred Products: Semglee, Insulin glargine-yfgn	REZVOGLAR KWIKPEN
Lupus		BENLYSTA
		LUPKYNIS
Myalept		MYALEPT
Neurokinin Receptor Antagonists		VEOZAH
Neurotrophic Keratitis		OXERVATE
Northera		droxidopa
		NORTHERA
Ocaliva		OCALIVA
Opioids ER		BELBUCA
		buprenorphine
		BUTRANS

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		CONZIP
		fentanyl
		HYDROCODONE BITARTRATE ER
		hydromorphone hcl er
		hydromorphone hydrochloride er
		HYSINGLA ER
		MORPHINE SULFATE ER
		MS CONTIN
		NUCYNTA ER
		OXYCODONE HCL ER
		OXYCODONE HYDROCHLORIDE ER
		OXYCONTIN
		OXYMORPHONE HYDROCHLORIDE ER
		OXYMORPHONE HYDROCHLORIDEER
		TRAMADOL HCL ER
		tramadol hydrochloride er
		XTAMPZA ER
Opzelura		OPZELURA
Otezla		OTEZLA
Oxbryta		OXBRYTA
Oxybate		LUMRYZ
		SODIUM OXYBATE
		XYREM
		XYWAV
Parathyroid Hormone Analog for Osteoporosis	Preferred Products: Tymlos, Forteo	FORTEO
	Preferred Products: Tymlos, Forteo	TERIPARATIDE
	Preferred Products: Tymlos, Forteo	TYMLOS
PCSK-9 Inhibitors	Preferred Product: Repatha	PRALUENT
	Preferred Product: Repatha	REPATHA
	Preferred Product: Repatha	REPATHA PUSHTRONEX SYSTEM
	Preferred Product: Repatha	REPATHA SURECLICK
Peanut Allergy		PALFORZIA INITIAL DOSE ESCALATION
		PALFORZIA LEVEL 1
		PALFORZIA LEVEL 10
		PALFORZIA LEVEL 11 (MAINTENANCE)
		PALFORZIA LEVEL 11 (TITRATION)
		PALFORZIA LEVEL 2
		PALFORZIA LEVEL 3
		PALFORZIA LEVEL 4

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		PALFORZIA LEVEL 5
		PALFORZIA LEVEL 6
		PALFORZIA LEVEL 7
		PALFORZIA LEVEL 8
		PALFORZIA LEVEL 9
Peginterferon		PEGASYS
Phenylketonuria		javygtor
		KUVAN
		PALYNZIQ
		sapropterin dihydrochloride
Procysbi		PROCYSBI
Pseudobulbar Affect		NUDEXTA
Pulmonary Arterial Hypertension		ADCIRCA
		ADEMPAS
		alyq
		ambrisentan
		bosentan
		LETAIRIS
		LIQREV
		OPSUMIT
		OPSYNVI
		ORENITRAM
		ORENITRAM TITRATION KIT MONTH 1
		ORENITRAM TITRATION KIT MONTH 2
		ORENITRAM TITRATION KIT MONTH 3
		REVATIO
		sildenafil citrate
		tadalafil
		TADLIQ
		TRACLEER
		TYVASO
		TYVASO DPI INSTITUTIONAL KIT
		TYVASO DPI MAINTENANCE KIT
		TYVASO DPI TITRATION KIT
		TYVASO REFILL
		TYVASO STARTER
		UPTRAVI
		UPTRAVI TITRATION PACK
		VENTAVIS

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		WINREVAIR
Pyrukynd		PYRUKYND
		PYRUKYND TAPER PACK
Radicava		RADICAVA ORS
		RADICAVA ORS STARTER KIT
Recorlev		RECORLEV
Relyvrio		RELYVRIO
Resmetirom		REZDIFFRA
Rezurock		REZUROCK
Risdiplam		EVRYSDI
Rivfloza		RIVFLOZA
SA Oncology		abiraterone acetate
		AFINITOR
		AFINITOR DISPERZ
		AKEEGA
		ALECENSA
		ALUNBRIG
		AUGTYRO
		AYVAKIT
		BALVERSA
	Preferred Product: Peginterferon	BESREMI
		bexarotene
	Preferred Products: generic imatinib, Sprycel	BOSULIF
		BRAFTOVI
		BRUKINSA
		CABOMETYX
		CALQUENCE
		capecitabine
		CAPRELSA
		COMETRIQ
		COPIKTRA
		COTELLIC
		DAURISMO
		ERIVEDGE
		ERLEADA
		erlotinib hydrochloride
		everolimus
		FOTIVDA
		FRUZAQLA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		GAVRETO
		gefitinib
		GILOTRIF
		GLEEVEC
		HYCAMTIN
		IBRANCE
		ICLUSIG
		IDHIFA
		imatinib mesylate
		IMBRUVICA
		INLYTA
		INQOVI
		INREBIC
		IRESSA
		IWILFIN
		JAKAFI
		JAYPIRCA
		KISQALI
		KISQALI FEMARA 200 DOSE
		KISQALI FEMARA 400 DOSE
		KISQALI FEMARA 600 DOSE
		KOSELUGO
		KRAZATI
		lapatinib ditosylate
		lenalidomide
		LENVIMA 10 MG DAILY DOSE
		LENVIMA 12MG DAILY DOSE
		LENVIMA 14 MG DAILY DOSE
		LENVIMA 18 MG DAILY DOSE
		LENVIMA 20 MG DAILY DOSE
		LENVIMA 24 MG DAILY DOSE
		LENVIMA 4 MG DAILY DOSE
		LENVIMA 8 MG DAILY DOSE
		LONSURF
		LORBRENA
		LUMAKRAS
		LYNPARZA
		LYSODREN
		LYTGOBI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		MATULANE
		MEKINIST
		MEKTOVI
		NERLYNX
		NEXAVAR
		NINLARO
		NUBEQA
		ODOMZO
		OGSIVEO
		OJEMDA
		OJJAARA
		ONUREG
		ORGOVYX
		ORSERDU
		pazopanib hydrochloride
		PEMAZYRE
		PIQRAY 200MG DAILY DOSE
		PIQRAY 250MG DAILY DOSE
		PIQRAY 300MG DAILY DOSE
		POMALYST
		QINLOCK
		RETEVMO
		REVLIMID
		REZLIDHIA
		ROZLYTREK
		RUBRACA
		RYDAPT
	Preferred Product: Iclusig	SCEMBLIX
		sorafenib
		sorafenib tosylate
		SPRYCEL
		STIVARGA
		sunitinib malate
		SUTENT
		TABRECTA
		TAFINLAR
		TAGRISSO
		TALZENNA
		TARCEVA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		TARGRETIN
	Preferred Products: generic imatinib, Sprycel	TASIGNA
		TAZVERIK
		TEMODAR
		temozolomide
		TEPMETKO
		THALOMID
		TIBSOVO
		torpenz
		tretinoin
		TRUQAP
		TRUSELTIQ
		TUKYSA
		TURALIO
		TYKERB
		VANFLYTA
		VENCLEXTA
		VENCLEXTA STARTING PACK
		VERZENIO
		VITRAKVI
		VIZIMPRO
		VONJO
		VOTRIENT
		WELIREG
		XALKORI
		XELODA
		XOSPATA
		XPOVIO
		XPOVIO 60 MG TWICE WEEKLY
		XPOVIO 80 MG TWICE WEEKLY
		XTANDI
		YONSA
		ZEJULA
		ZELBORAF
		ZOLINZA
		ZYDELIG
		ZYKADIA
		ZYTIGA
Samsca		SAMSCA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		tolvaptan
Signifor		SIGNIFOR
Skyclarys		SKYCLARYS
Spevigo		SPEVIGO
SSIA		NUPLAZID
Strensiq		STRENSIQ
Subcutaneous Immune Globulins		CUTAQUIG
		CUVITRU
		GAMMAGARD LIQUID
		GAMMAKED
		GAMUNEX-C
		HIZENTRA
		HYQVIA
		XEMBIFY
Substrate Reduction Therapy		CERDELGA
		miglustat
		OPFOLDA
		yargesa
		ZAVESCA
Sucraid		SUCRAID
Sunosi		SUNOSI
Tarpeyo		TARPEYO
Tavneos		TAVNEOS
Tezspire		TEZSPIRE
Thrombopoietin Receptor Agonists		ALVAIZ
		DOPTELET
		MULPLETA
		PROMACTA
		TAVALISSE
Topical AK Basal Cell Carcinoma Warts Agents		CARAC
		diclofenac sodium
		EFUDEX
		FLUOROURACIL
		imiquimod
		imiquimod pump
		KLISYRI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		TOLAK
		ZYCLARA
		ZYCLARA PUMP
Topical AK Basal Cell Carcinoma Warts Agents		FLUOROURACIL
Topical Antifungals (Ciclo/Efina/Tavab)		ciclodan
		ciclopirox nail lacquer
		JUBLIA
		KERYDIN
		tavaborole
Topical Doxepin		doxepin hydrochloride
		PRUDOXIN
		ZONALON
Topical NSAID		DICLOFENAC EPOLAMINE
		FLECTOR
		LICART
Topiramate ER		QUDEXY XR
		topiramate er
		TROKENDI XR
Transmucosal Immediate Release Fentanyl		ACTIQ
		FENTANYL CITRATE
		fentanyl citrate oral transmucosal
		FENTORA
		LAZANDA
		SUBSYS
Urea Cycle Disorders		BUPHENYL
		OLPRUVA
		PHEBURANE
		RAVICTI
		sodium phenylbutyrate
Verkazia		VERKAZIA
Verquvo		VERQUVO
Vijoice		VIJOICE
VMAT2 Inhibitors		AUSTEDO
		AUSTEDO PATIENT TITRATION KIT
		AUSTEDO XR
		AUSTEDO XR PATIENT TITRATION KIT
		INGREZZA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		tetrabenazine
		XENAZINE
Vowst		VOWST
Voxzogo		VOXZOGO
Voydeya		VOYDEYA
Vtama		VTAMA
Wakix		WAKIX
Weight Loss Agents		ADIPEX-P
		benzphetamine hcl
		CONTRACE
		diethylpropion hcl
		DIETHYLPROPION HCL ER
		diethylpropion hydrochloride
		DIETHYLPROPION HYDROCHLORIDE ER
		LOMAIRA
		ORLISTAT
		phendimetrazine tartrate
		PHENDIMETRAZINE TARTRATE ER
		phentermine hcl
		phentermine hydrochloride
		QSYMIA
		XENICAL
Weight Management		SAXENDA
		WEGOVY
		ZEPBOUND
Winlevi		WINLEVI
Xermelo		XERMELO
Xhance		XHANCE
Xolair		XOLAIR
Xphozah		XPHOZAH
Zeposia	Preferred Products for UC: Refer to Policy	ZEPOSIA
	Preferred Products for UC: Refer to Policy	ZEPOSIA 7-DAY STARTER PACK
	Preferred Products for UC: Refer to Policy	ZEPOSIA STARTER KIT
Zokinvy		ZOKINVY
Zoryve		ZORYVE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.